ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
ceritinib Sensitive: A2 - Guideline
|
ceritinib Sensitive: A2 - Guideline
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
lorlatinib Sensitive: A2 - Guideline
|
lorlatinib Sensitive: A2 - Guideline
|
ROS1 rearrangement
|
Lung Cancer
|
ROS1 rearrangement
|
Lung Cancer
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
ROS1 rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
ROS1 rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
ROS1 rearrangement
|
LUAD
|
ROS1 rearrangement
|
LUAD
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
ROS1 rearrangement
|
LUAD
|
ROS1 rearrangement
|
LUAD
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
brigatinib Sensitive: C3 – Early Trials
|
brigatinib Sensitive: C3 – Early Trials
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
WX-0593 Sensitive: C3 – Early Trials
|
WX-0593 Sensitive: C3 – Early Trials
|
ROS1 rearrangement
|
LUAD
|
ROS1 rearrangement
|
LUAD
|
ceritinib Sensitive: C4 – Case Studies
|
ceritinib Sensitive: C4 – Case Studies
|